Evidence map›Paper›PMID 33570602›Full record

GuidelineBlood advances2021

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Gary H Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K Hicks, Alok A Khorana, Andrew D Leavitt, Agnes Y Y Lee, Fergus Macbeth, Rebecca L Morgan and 6 more

Erratum issuedOpen access · goldAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 453 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
453citing papers in PubMed, 15 pooled it
111.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

453 citing papers in PubMed, 15 syntheses or guidelines pooled it, 809 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Review

393 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 7 countries.

Gary H LymanDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
Marc CarrierDepartment of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, ON, Canada.
Cihan AyClinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Marcello Di NisioDepartment of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy.
Lisa K HicksDivision of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Alok A KhoranaCleveland Clinic and Case Comprehensive Cancer Center, Cleveland, OH.
Andrew D LeavittDepartment of Laboratory Medicine and.
Agnes Y Y LeeDivision of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Fergus MacbethBristol, United Kingdom.
Rebecca L MorganDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Simon NobleDivision of Population Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom.
Elizabeth A SextonSalt Lake City, UT.
David StenehjemCollege of Pharmacy, University of Minnesota, Duluth, MN.
Wojtek WierciochDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Lara A KahaleAmerican University of Beirut (AUB) Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Center, American University of Beirut, Beirut, Lebanon; and.
Pablo Alonso-CoelloCochrane Iberoamérica, Biomedical Research Institute Sant Pau-CIBERESP, Barcelona, Spain.
Impact · CAAmerican University of Beirut · LBCardiff University · GBCleveland Clinic · USComprehensive Cancer Center Vienna · ATIberoamerican Cochrane Centre · ESSt. Michael's Hospital · CAUniversity of British Columbia · CAUniversity of California, San Francisco · USUniversity of Chieti-Pescara · ITUniversity of Minnesota, Duluth · USUniversity of Ottawa · CAUniversity of Washington · US

Funding

Marie Curie MCCC-FCO-11-C
6 · The paper itself

Abstract

backgroundVenous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality.

objectiveThese evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer.

methodsASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The guideline development process was supported by updated or new systematic evidence reviews. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess evidence and make recommendations.

resultsRecommendations address mechanical and pharmacological prophylaxis in hospitalized medical patients with cancer, those undergoing a surgical procedure, and ambulatory patients receiving cancer chemotherapy. The recommendations also address the use of anticoagulation for the initial, short-term, and long-term treatment of VTE in patients with cancer.

conclusionsStrong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for initial treatment of VTE in patients with cancer. Conditional recommendations include using thromboprophylaxis in hospitalized medical patients with cancer, LMWH or fondaparinux for surgical patients with cancer, LMWH or direct oral anticoagulants (DOAC) in ambulatory patients with cancer receiving systemic therapy at high risk of VTE and LMWH or DOAC for initial treatment of VTE, DOAC for the short-term treatment of VTE, and LMWH or DOAC for the long-term treatment of VTE in patients with cancer.

Indexed as

HematologyNeoplasmsVenous ThromboembolismAnticoagulantsHeparin, Low-Molecular-WeightHumansUnited StatesAnticoagulantsHeparin, Low-Molecular-Weight

Identifiers

PMID33570602
PMCPMC7903232
OpenAlexW3127460195

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.